Novavax Future Growth

Future criteria checks 3/6

Novavax's revenue is forecast to decline at 6.9% per annum while its annual earnings are expected to grow at 71.5% per year. EPS is expected to grow by 79.1% per annum.

Key information

71.5%

Earnings growth rate

79.1%

EPS growth rate

Biotechs earnings growth	25.1%
Revenue growth rate	-6.9%
Future return on equity	n/a
Analyst coverage	Good
Last updated	19 May 2024

Recent future growth updates

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13

Recent updates

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Sep 06

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

Mar 05

Earnings and Revenue Growth Forecasts

NasdaqGS:NVAX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	613	24	42	-37	3
12/31/2025	586	-116	-693	-236	6
12/31/2024	952	19	289	416	6
3/31/2024	997	-399	-514	-472	N/A
12/31/2023	984	-545	-773	-714	N/A
9/30/2023	1,050	-549	-727	-655	N/A
6/30/2023	1,597	-587	-737	-654	N/A
3/31/2023	1,359	-1,155	-753	-653	N/A
12/31/2022	1,982	-658	-509	-416	N/A
9/30/2022	1,847	-1,322	-728	-641	N/A
6/30/2022	1,291	-1,476	-814	-744	N/A
3/31/2022	1,403	-1,318	-489	-429	N/A
12/31/2021	1,146	-1,744	265	323	N/A
9/30/2021	1,204	-1,075	454	537	N/A
6/30/2021	1,182	-950	593	672	N/A
3/31/2021	919	-615	575	644	N/A
12/31/2020	476	-418	-97	-43	N/A
9/30/2020	205	-273	49	62	N/A
6/30/2020	50	-93	32	37	N/A
3/31/2020	18	-115	-110	-109	N/A
12/31/2019	19	-133	-138	-137	N/A
9/30/2019	16	-150	-160	-158	N/A
6/30/2019	21	-177	-162	-159	N/A
3/31/2019	29	-182	-171	-169	N/A
12/31/2018	34	-185	-186	-185	N/A
9/30/2018	39	-186	-184	-183	N/A
6/30/2018	39	-186	-196	-194	N/A
3/31/2018	35	-186	-169	-166	N/A
12/31/2017	31	-184	N/A	-144	N/A
9/30/2017	26	-190	N/A	-162	N/A
6/30/2017	21	-212	N/A	-181	N/A
3/31/2017	17	-247	N/A	-230	N/A
12/31/2016	15	-280	N/A	-259	N/A
9/30/2016	16	-302	N/A	-249	N/A
6/30/2016	19	-269	N/A	-215	N/A
3/31/2016	31	-210	N/A	-165	N/A
12/31/2015	36	-157	N/A	-126	N/A
9/30/2015	37	-110	N/A	-91	N/A
6/30/2015	39	-96	N/A	-78	N/A
3/31/2015	33	-94	N/A	-77	N/A
12/31/2014	31	-83	N/A	-67	N/A
9/30/2014	33	-65	N/A	-60	N/A
6/30/2014	29	-61	N/A	-59	N/A
3/31/2014	25	-56	N/A	-55	N/A
12/31/2013	21	-52	N/A	-45	N/A
9/30/2013	17	-46	N/A	-36	N/A
6/30/2013	18	-38	N/A	-26	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NVAX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: NVAX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NVAX is expected to become profitable in the next 3 years.

Revenue vs Market: NVAX's revenue is expected to decline over the next 3 years (-6.9% per year).

High Growth Revenue: NVAX's revenue is forecast to decline over the next 3 years (-6.9% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NVAX's Return on Equity is forecast to be high in 3 years time

Novavax Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 13%

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

Consensus EPS estimates upgraded to US$0.55 loss

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss

Recent updates

President of Research & Development recently sold US$384k worth of stock

Consensus revenue estimates increase by 13%

President of Research & Development notifies of intention to sell stock

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

New major risk - Financial position

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

Novavax, Inc., Annual General Meeting, Jun 13, 2024

Consensus EPS estimates upgraded to US$0.55 loss

New minor risk - Profitability

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss

President of Research & Development exercised options and sold US$14k worth of stock

Consensus estimates of losses per share improve by 28%

Price target decreased by 20% to US$15.40

Novavax: Another Day Older And Deeper In

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Full year 2023 earnings: EPS and revenues miss analyst expectations

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

Consensus EPS estimates upgraded to US$0.39 loss, revenue downgraded

New minor risk - Share price stability

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

CEO & Director exercised options and sold US$171k worth of stock

Price target increased by 15% to US$23.25

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

No longer forecast to breakeven

New major risk - Shareholder dilution

Price target increased by 11% to US$24.50

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

Forecast to breakeven in 2024

Consensus estimates of losses per share improve by 11%

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 12%

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

Consensus estimates of losses per share improve by 24%

New minor risk - Profitability

New major risk - Share price stability

Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid

Consensus EPS estimates fall by 35%

Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Forecast to breakeven in 2025

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 16% to US$39.33

Consensus EPS estimates upgraded to US$4.96 loss, revenue downgraded

Consensus revenue estimates decrease by 25%

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

No longer forecast to breakeven

Price target increased by 23% to US$68.33